Scientists at the Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma. The researchers showed that reprogramming myeloid cells, a type of immune cell that glioblastoma tumors co-opt to protect themselves, while simultaneously boosting cancer-fighting T cells shrank the tumors and prevented them from coming back.
Two studies led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center provide insight into how the immune system can successfully be activated against glioblastoma while revealing why these therapies have historically fallen short.
